Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer

PLoS Pathogens

Volumn 12, Issue 12, 2016, Pages

  Khasnis, Mukta D ^a   Halkidis, Konstantine ^a,b   Bhardwaj, Anshul ^a   Root, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; CRYSTALLOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; POLYACRYLAMIDE GEL ELECTROPHORESIS; RECEPTOR BINDING; STOICHIOMETRY; WESTERN BLOTTING; CELL LINE; CHEMISTRY; MOLECULAR MODEL; PHYSIOLOGY; PROTEIN CONFORMATION; VIRUS ENTRY;

CELL LINE; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; VIRUS INTERNALIZATION;

EID: 85008217198     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006098     Document Type: Article

References (90)

1. Checkley MA, Luttge BG, Freed EO, HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol. 2011Jul22;410(4):582–608. doi: 10.1016/j.jmb.2011.04.04221762802
2. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD, Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2006Aug;2(8):e83. doi: 10.1371/journal.ppat.002008316933990
3. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008Sep4;455(7209):109–13. doi: 10.1038/nature0715918668044
4. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010;6(12):e1001249. doi: 10.1371/journal.ppat.100124921203482
5. White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, et al. Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol. 2011Dec;85(23):12114–23. doi: 10.1128/JVI.05297-1121937655
6. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013Dec20;342(6165):1484–90. doi: 10.1126/science.124562724179160
7. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013Dec20;342(6165):1477–83. doi: 10.1126/science.124562524179159
8. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014Oct23;514(7523):455–61. doi: 10.1038/nature1380825296255
9. Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol. 2015Jul;22(7):522–31. doi: 10.1038/nsmb.305126098315
10. Lee JH, Ozorowski G, Ward AB, Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science. 2016Mar4;351(6277):1043–8. doi: 10.1126/science.aad245026941313
11. Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell. 2016May5;165(4):813–26. doi: 10.1016/j.cell.2016.04.01027114034
12. Chan DC, Fass D, Berger JM, Kim PS, Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997Apr18;89(2):263–73. 9108481
13. Eckert DM, Kim PS, Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem. 2001;70:777–810. doi: 10.1146/annurev.biochem.70.1.77711395423
14. Harrison SC, Viral membrane fusion. Nat Struct Mol Biol. 2008Jul;15(7):690–8. doi: 10.1038/nsmb.145618596815
15. Melikyan GB, Membrane fusion mediated by human immunodeficiency virus envelope glycoprotein. Curr Top Membr. 2011;68:81–106. doi: 10.1016/B978-0-12-385891-7.00004-021771496
16. Sattentau QJ, Moore JP, Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med. 1991Aug1;174(2):407–15. 1713252
17. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA, Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998Jun18;393(6686):648–59. doi: 10.1038/314059641677
18. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC, Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 2005Feb24;433(7028):834–41. doi: 10.1038/nature0332715729334
19. Berger EA, Murphy PM, Farber JM, Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657–700. doi: 10.1146/annurev.immunol.17.1.65710358771
20. Melikyan GB, Platt EJ, Kabat D, The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology. 2007;4:55. doi: 10.1186/1742-4690-4-5517686153
21. Platt EJ, Shea DM, Rose PP, Kabat D, Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J Virol. 2005Apr;79(7):4357–68. doi: 10.1128/JVI.79.7.4357-4368.200515767436
22. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996Nov14;384(6605):179–83. doi: 10.1038/384179a08906795
23. Moore JP, McKeating JA, Weiss RA, Sattentau QJ, Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990Nov23;250(4984):1139–42. 2251501
24. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med. 2011Mar14;208(3):439–54. doi: 10.1084/jem.2010190721357743
25. Kliger Y, Aharoni A, Rapaport D, Jones P, Blumenthal R, Shai Y, Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study. J Biol Chem. 1997May23;272(21):13496–505. 9153194
26. Dimitrov AS, Xiao X, Dimitrov DS, Blumenthal R, Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J Biol Chem. 2001Aug10;276(32):30335–41. doi: 10.1074/jbc.M10378820011397808
27. Cai L, Gochin M, Liu K, Biochemistry and biophysics of HIV-1 gp41—membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem. 2011Dec;11(24):2959–84. 22044229
28. Root MJ, Steger HK, HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des. 2004;10(15):1805–25. 15180542
29. Berkhout B, Eggink D, Sanders RW, Is there a future for antiviral fusion inhibitors?Curr Opin Virol. 2012Feb;2(1):50–9. doi: 10.1016/j.coviro.2012.01.00222440966
30. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC, Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997May22;387(6631):426–30. doi: 10.1038/387426a09163431
31. Lu M, Kim PS, A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn. 1997Dec;15(3):465–71. doi: 10.1080/07391102.1997.105089589439994
32. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W, Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010May;6(5):e1000880. doi: 10.1371/journal.ppat.100088020463810
33. Chan DC, Kim PS, HIV entry and its inhibition. Cell. 1998May29;93(5):681–4. 9630213
34. Salzwedel K, Berger EA, Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proc Natl Acad Sci U S A. 2000Nov7;97(23):12794–9. doi: 10.1073/pnas.23043849711050186
35. Salzwedel K, Berger EA, Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. Retrovirology. 2009;6:75. doi: 10.1186/1742-4690-6-7519671162
36. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med. 2011Jul4;208(7):1419–33. doi: 10.1084/jem.2011019621646396
37. Ackers GK, Perrella M, Holt JM, Denisov I, Huang Y, Thermodynamic stability of the asymmetric doubly-ligated hemoglobin tetramer (alpha+CNbeta+CN)(alphabeta): methodological and mechanistic issues. Biochemistry. 1997Sep9;36(36):10822–9. doi: 10.1021/bi971382x9312272
38. Ackers GK, Holt JM, Asymmetric cooperativity in a symmetric tetramer: human hemoglobin. J Biol Chem. 2006Apr28;281(17):11441–3. doi: 10.1074/jbc.R50001920016423822
39. Kilgore NR, Salzwedel K, Reddick M, Allaway GP, Wild CT, Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol. 2003Jul;77(13):7669–72. doi: 10.1128/JVI.77.13.7669-7672.200312805467
40. Chan DC, Chutkowski CT, Kim PS, Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A. 1998Dec22;95(26):15613–7. 9861018
41. Jiang S, Lin K, Strick N, Neurath AR, HIV-1 inhibition by a peptide. Nature. 1993Sep9;365(6442):113. doi: 10.1038/365113a08371754
42. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T, A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A. 1992Nov1;89(21):10537–41. 1438243
43. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ, Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994Oct11;91(21):9770–4. 7937889
44. Root MJ, Kay MS, Kim PS, Protein design of an HIV-1 entry inhibitor. Science. 2001Feb2;291(5505):884–8. 11229405
45. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS, Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell. 1999Oct1;99(1):103–15. 10520998
46. Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, Katinger H, et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol. 1996Sep;77 (Pt 9):2001–8.
47. Louis JM, Bewley CA, Clore GM, Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem. 2001Aug3;276(31):29485–9. doi: 10.1074/jbc.C10031720011418583
48. Furuta RA, Wild CT, Weng Y, Weiss CD, Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol. 1998Apr;5(4):276–9. 9546217
49. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R, Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol. 1998Jan26;140(2):315–23. 9442107
50. Steger HK, Root MJ, Kinetic dependence to HIV-1 entry inhibition. J Biol Chem. 2006Sep1;281(35):25813–21. doi: 10.1074/jbc.M60145720016803885
51. Miyauchi K, Kozlov MM, Melikyan GB, Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog. 2009Sep;5(9):e1000585. doi: 10.1371/journal.ppat.100058519763181
52. Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS, The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol. 2005Jan;79(1):106–15. doi: 10.1128/JVI.79.1.106-115.200515596806
53. Markosyan RM, Cohen FS, Melikyan GB, HIV-1 Envelope Proteins Complete Their Folding into Six-helix Bundles Immediately after Fusion Pore Formation. Mol Biol Cell. 2003Mar;14(3):926–38. doi: 10.1091/mbc.E02-09-057312631714
54. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS, Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol. 2000Oct16;151(2):413–23. 11038187
55. Kahle KM, Steger HK, Root MJ, Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 2009Nov;5(11):e1000674. doi: 10.1371/journal.ppat.100067419956769
56. Hamburger AE, Kim S, Welch BD, Kay MS, Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem. 2005Apr1;280(13):12567–72. doi: 10.1074/jbc.M41277020015657041
57. Eckert DM, Shi Y, Kim S, Welch BD, Kang E, Poff ES, et al. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci. 2008Dec;17(12):2091–100. doi: 10.1110/ps.038273.10818802030
58. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A. 2002Dec10;99(25):16249–54. doi: 10.1073/pnas.25246939912444251
59. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, et al. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol. 2004May;78(10):5476–85. doi: 10.1128/JVI.78.10.5476-5485.200415113926
60. Platt EJ, Durnin JP, Kabat D, Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol. 2005Apr;79(7):4347–56. doi: 10.1128/JVI.79.7.4347-4356.200515767435
61. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J, Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol. 1990Dec;64(12):5701–7. 2243375
62. Thali M, Olshevsky U, Furman C, Gabuzda D, Li J, Sodroski J, Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol. 1991Sep;65(9):5007–12. 1870209
63. Champagne K, Shishido A, Root MJ, Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem. 2009Feb6;284(6):3619–27. doi: 10.1074/jbc.M80926920019073602
64. Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW, Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol. 2007Apr;81(7):3240–50. doi: 10.1128/JVI.02413-0617251281
65. Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol. 2004Nov;78(22):12428–37. doi: 10.1128/JVI.78.22.12428-12437.200415507629
66. Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol. 2010Nov;84(21):11235–44. doi: 10.1128/JVI.01339-1020719956
67. Moore JP, McKeating JA, Norton WA, Sattentau QJ, Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J Virol. 1991Mar;65(3):1133–40. 1995942
68. McKeating JA, McKnight A, Moore JP, Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol. 1991Feb;65(2):852–60. 1898972
69. Yang X, Kurteva S, Ren X, Lee S, Sodroski J, Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol. 2006May;80(9):4388–95. doi: 10.1128/JVI.80.9.4388-4395.200616611898
70. Wilson IA, Skehel JJ, Wiley DC, Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981Jan29;289(5796):366–73. 7464906
71. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO, Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008Jul10;454(7201):177–82. doi: 10.1038/nature0708218615077
72. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A. 2005Oct11;102(41):14759–64. doi: 10.1073/pnas.050692710216203977
73. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A. 2010Jun8;107(23):10655–60. doi: 10.1073/pnas.100426110720483992
74. Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, Miller MD, et al. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs. 2009Sep-Oct;1(5):462–74. 20065653
75. Gustchina E, Louis JM, Frisch C, Ylera F, Lechner A, Bewley CA, et al. Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology. 2009Oct10;393(1):112–9. doi: 10.1016/j.virol.2009.07.01919695655
76. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM, A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol. 2007Dec;81(23):12946–53. doi: 10.1128/JVI.01260-0717898046
77. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology. 2008Jul20;377(1):170–83. doi: 10.1016/j.virol.2008.04.00518499210
78. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996Jun20;381(6584):661–6. doi: 10.1038/381661a08649511
79. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997Oct;71(10):7478–87. 9311827
80. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L, Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol. 1997Feb;71(2):1657–61. 8995695
81. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses. 1994Apr;10(4):371–81. doi: 10.1089/aid.1994.10.3718068416
82. Chen BK, Saksela K, Andino R, Baltimore D, Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol. 1994Feb;68(2):654–60. 7507183
83. Edelhoch H, Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry. 1967Jul;6(7):1948–54. 6049437
84. Gildea RJ, Waterman DG, Parkhurst JM, Axford D, Sutton G, Stuart DI, et al. New methods for indexing multi-lattice diffraction data. Acta Crystallogr D Biol Crystallogr. 2014Oct;70(Pt 10):2652–66. doi: 10.1107/S139900471401703925286849
85. Evans PR, Murshudov GN, How good are my data and what is the resolution?Acta Crystallogr D Biol Crystallogr. 2013Jul;69(Pt 7):1204–14. doi: 10.1107/S090744491300006123793146
86. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, Phaser crystallographic software. J Appl Crystallogr. 2007Aug1;40(Pt 4):658–74. doi: 10.1107/S002188980702120619461840
87. Emsley P, Cowtan K, Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004Dec;60(Pt 12 Pt 1):2126–32.
88. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol. 2007Apr1;178(7):4424–35. 17372000
89. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.8. 2015.
90. Wang Q, Cheng F, Lu M, Tian X, Ma J, Crystal structure of unliganded influenza B virus hemagglutinin. J Virol. 2008Mar;82(6):3011–20. doi: 10.1128/JVI.02477-0718184701